FDA Determines Regulatory Review Period for ULORIC Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for ULORIC, a human drug product, as required by law. This decision was prompted by a patent extension application submitted to the US Department of Commerce's Director of Patents and Trademarks.